Ozempic ‘microdosing’ is new weight-loss trend
GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...
New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...
Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.
Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.
4don MSN
While West Virginia's employee health insurance program covers drugs like Ozempic for people with type 2 diabetes, officials ...
Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback